PURAPHARM (01498) announced that, in accordance with the patent license agreement dated July 25, 2025, the company allotted and issued 93.4884 million consideration shares on October 30, 2025. Additionally, under the subscription agreement dated July 25, 2025, the company allotted and issued 46.512 million subscription shares on the same date.